Recursion’s Incoming CEO Needs To Prove That AI Drug Development Can Pay Off

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week.
C&EN

Inverse Electron-Demand Diels–Alder Reaction of exo-Imidazolidin-2-One Dienes with In Situ Generated 1,2-Diaza-1,3-Butadienes and α-Nitrosostyrenes

Innovation Research Center of Chiral Drugs, Institute for Advanced Study, Chengdu University, Chengdu 610106, China ...
IEEE

1+1>2: A Dual-Function Defense Framework for Adversarial Example Mitigation

Abstract: Current state-of-the-art plug-and-play countermeasures for mitigating adversarial examples (i.e., purification and detection) exhibit several fatal limitations, impeding their deployment in ...
IEEE

A Quadratic Programming Approach for Microwave Imaging

Abstract: Microwave imaging is an emerging technique with applications in various areas, such as geoscience, aviation, and medicine. One of the classic methodologies to address this inverse problem is ...